SELL and neoplasm: To verify this hypothesis, the LD201t1 aptamer that can specifically recognize CD62L (highly expressed on the surfaces of T-cell membranes) and tumor cell-targeting aptamers (sgc8c, a CCRF-CEM targeting aptamer; TD05, a Ramos targeting aptamer) were chosen to construct the designed CBApts.